- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Engene Holdings Inc.
Industry Sector: HealthTechnology
CEO: Ronald H. W. Cooper
Number Of Employees: 57
Enterprise Value: $120,991,762
PE Ratio: -1.98
Exchange/Ticker 1: NASDAQ:ENGN
Exchange/Ticker 2: N/A
Latest Market Cap: $153,952,400
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Jul 24, 2024
Management Tracks
Trimarchi becomes president, COO of BridgeBio
Plus: New CEO, CFO at Beacon and updates from enGene, Broken String and Nashville
BioCentury | Apr 10, 2024
Management Tracks
PureTech’s Zohar takes CEO role at new portfolio company targeting CNS
Plus: AskBio hires former Prevail CSO, and updates from Illumina, Xencor, Adcentrx, enGene and more
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Feb 16, 2024
Management Tracks
CEO Hanson leaving enGene
Plus: Compugen names Mahler CMO and updates from Merck, Navega, RAPT and Ocuphire
BioCentury | Jan 31, 2024
Management Tracks
George Daneker to head clinical oncology at Myriad
Plus: TScan hires Jason Amello as CFO, and updates from CytoDyn, enGene and the Scleroderma Research Foundation
BioCentury | Nov 30, 2023
Management Tracks
Kerr, Zimmermann leaving Generation Bio amid restructuring, headcount cuts
Plus: Sáez becomes Agomab’s chief development officer and updates from Forest Road, PDS, enGene and Pyxis
BioCentury | Nov 1, 2023
Deals
Nov. 1 Quick Takes: AZ takes stake in Cellectis, eyes 25 targets in deal
Plus: RTW acquiring Arix Bioscience, and updates from Aldeyra, AbbVie, Silence, Lilly, Sitryx and more
Items per page:
1 - 8 of 8